Nanobiotix receives FDA approval for first immuno-oncology trial

[News]

NANOBIOTIX, a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the U.S. Food and Drug Administration has approved its Investigational New Drug Application for NBTXR3, a first-in-class nanoparticle designed for direct injection into cancerous tumors, activated by stereotactic ablative radiotherapy (SABR) and administered in combination with an anti-PD1 antibody (nivolumab or pembrolizumab).

More... (https://www.news-medical.net/news/20171226/Nanobiotix-receives-FDA-approval-for-first-immuno-oncology-trial.aspx)